Prognostic Relevance of Human Telomerase Reverse Transcriptase (hTERT) Expression in Patients with Gall Bladder Disease and Carcinoma

  • Deblakshmi, Raj Kumari (Department of Biotechnology, Gauhati University) ;
  • Deka, Manab (Department of Biotechnology, Gauhati University) ;
  • Saikia, Anjan Kumar (Medicinal and Gastroenterology Unit, Central Hospital NF Railway) ;
  • Sharma, Bir Kumar (Department of General Surgery, Regional Institute of Medical Sciences) ;
  • Singh, Nidhi (Department of Biotechnology, Gauhati University) ;
  • Das, NN (Department of HPB and Liver Transplant Surgery, Downtown Hospital) ;
  • Bose, Sujoy (Department of Biotechnology, Gauhati University)
  • Published : 2015.04.14


Background: Gallbladder carcinoma (GBC) has been stated as an Indian disease, with the highest number of cases being reported from certain districts of northeast India, which has an ethnically distinct population. Unfortunately there are no scientific reports on the underlying molecular mechanisms associated with the pathogenesis of the disease from this region. Aim: The present study evaluated the role of differential expression of human telomerase reverse transcriptase (hTERT) in the development of gall bladder anomalies. Materials and Methods: Blood and tissue samples were collected from patients undergoing routine surgical resection for clinically proven cases of gallbladder disease {cholelithiasis (CL, n=50), cholecystitis (CS, n=40) and GBC (n=30) along with adjacent histopathologically proved non-neoplastic controls (n=15)} with informed consent. Whole blood was also collected from age and sex matched healthy controls (n=25) for comparative analysis. Differential hTERT mRNA expression was evaluated by semi-quantitative rt-PCR and real-time PCR based analysis using ${\beta}$-actin as an internal control. Evaluation of differential hTERT protein expression was studied by Western blot analysis and immunoflourescence. Statistical analysis for differential expression and co-relation was performed by SPSSv13.0 software. Results: Gallbladder anomalies were mostly prevalent in females. The hTERT mRNA and protein expression increased gradiently from normal


  1. Baez S, Tsuchiya Y, Calvo A, et al (2010). Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. World J Gastroenterol, 16, 372-8.
  2. Baichoo E, Boardman LA (2014). Toward a molecular classification of colorectal cancer :the role of telomere length. Front Oncol. 4, 158.
  3. Blasco MA, Hahn WC (2003). Evolving views of telomerase and cancer. Trends Cell Biol. 13, 289-4.
  4. Cerni C (2000). Telomeres, telomerase, and myc. An update. Mutat Res, 462, 31-7.
  5. Cesare AJ, Reddel RR (2010). Alternative lengthening of telomeres. Models, mechanisms, and implications. Nat Rev Genet, 11, 319-30.
  6. Cheng YB, Guo LP, Yao P, et al (2014). Telomerase and hTERT: Can they serve as markers for gastric cancer diagnosis? World J Gastroenterol, 20, 6615-9
  7. David L, Nahrwold DL, Dawes LG (1997). Biliary neoplasms in surgery In: Greenfield LJ (ed) Scientific Principles and Practice, 2nd Edn. Philadelphia Raven, pp 1056-6.
  8. Feng J, Funk WW, Wang SS, et al (1984). The RNA component of human telomerase. Science, 269, 1236-41.
  9. Fujita Y, Fujikane T, Fujiuchi S, et al (2003). The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with non small cell lung carcinoma. Cancer, 98, 1008-3.
  10. Fukui T, Nonomura N, Tokizane T, et al (2001). Clinical evaluation of human telomerase catalytic subunit in bladder washings from patients with bladder cancer, Mol Urol, 5, 19-3.
  11. Greider CW, Blackburn EH (1985). Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell, 43, 405-3.
  12. Greider CW (1991). Telomeres. Curr Opin Cell Biol, 3, 444-1.
  13. Hiyama E, Gollahon L, Kataoka T, et al (1996). Telomerase activity in human breast tumors. J Natl Cancer Inst, 17, 116-2.
  14. Hiyama E, Hiyama K (2003). Telomerase as tumor marker. Cancer Lett, 194, 221-3.
  15. Hsing AW, Gao YT, Han TQ, et al (2007). Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer, 97, 1577-2.
  16. Ito H, Kyo S, Kanaya T, et al (1998). Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer, Clin Cancer Res, 4, 2807-10.
  17. Kapoor V K, McMichael AJ (2003). Gallbladder cancer: An 'Indian' disease. National Med J India, 16, 209-2.
  18. Kawahara R, Odo M, Kinoshita H, (2007). Analysis of hTERT mRNA expression in biliary tract and pancreatic cancer. J Hepatobiliary Pancreat Surg, 14189-3.
  19. Kim K H, Kaminker P, Campisi J (2002). Telomerase, aging and cancer: in search of a happy ending. Oncogene, 21, 503-1.
  20. Kyo S, Kanaya T, Takakura M, Tanaka M, Inoue, M (1999). Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer, 80, 60-3.<60::AID-IJC12>3.0.CO;2-E
  21. Lerma E, Mora J (2005). Telomerase activity in "suspicious" thyroid cytology. Cancer Cancer Cytopathol, 105, 492-7.
  22. Li W, Li L, Liu Z, et al (2008). Expression of the full-length telomerase reverse transcriptase (hTERT) transcript in both malignant and normal gastric tissues. Cancer Lett, 260, 28-6.
  23. Luzar B, Poljak M, Cor A, Klopcic U, Ferlan-Marolt V (2005). Expression of human telomerase catalytic protein in gallbladder carcinogenesis. J Clin Pathol, 58, 820-5.
  24. Malik A Imitiaz (2004). Gall bladder cancer: current status. Expert Opin Pharmacother, 5, 1271-7.
  25. Miura N, Nakamura H, Sato R, et al (2006). Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci, 97, 1366-3.
  26. Miura N, Maeda Y, Kanbe T, et al (2005). Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res, 11, 3205-9.
  27. NakayamaJ, TaharaH, Tahara E, et al (1998). Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet, 18, 65-68.
  28. Nandakumar A, Gupta PC, Gangadharan P, Visweswara RN, Parkin DM (2005). Geographic pathology revisited: development of an atlas of cancer in India. Int J Cancer, 116, 740-4.
  29. NCRP:Consolidated Report on Population Based Cancer Registries (2011-2012). National Cancer Registry Programme (Indian Council of Medical Research), Bangalore.
  30. Hamdani NH, Qadri SK, AggarwallaRB, et al (2012). Clinicopathological study of gall bladder carcinoma with special reference to gallstones: our 8-year experience from Eastern India. Asian Pac J Cancer Prev, 13, 5613-7
  31. O'Sullivan JN, Bronner MP, Brentnall TA, et al (2002). Chromosomal instability in ulcerative colitisis related to telomere shortening. NatGenet, 32, 280-4.
  32. Ohuchida K, Mizumoto K, Ogura Y, et al (2005). Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger rna levels in pancreatic juice samples for the diagnosis of pancreatic cancer. Clin Cancer Res, 11, 2285-2.
  33. Poole J C, Andrews LG.Tollefsbol TO (2001). Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene, 269, 1-12.
  34. Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer, 118, 1591-2.
  35. Ryhu M (1995). Telomeres, telomerase, immortality. J Natl Cancer Inst, 87, 885-4.
  36. Sanjeev KM, Tewari M, Kumar M, MK, Shukla HS (2011). Expression pattern of tumor endothelial marker 8 protein in gallbladder carcinomas. Asian Pac J Cancer Prev, 12, 507-2
  37. Shay JW(1997). Telomerase in human development and cancer. J Cell Physiol, 173, 266-70.<266::AID-JCP33>3.0.CO;2-B
  38. Shukla VK, Chauhan VS, Kumar M (2006). Telomerase activation - one step on the road to carcinoma of the gall bladder. Anticancer Res, 26, 4761-6.
  39. Takakura M, Kyo S, Kanaya T, et al (1998). Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res, 58, 1558-1.
  40. Tazuma S, Kajiyama G (2001). Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch Surg, 386, 224-9.
  41. Uchida N, Tsutsui K, Ezaki T, Fukuma H, Kobara H, et al (2003). Combination of assay human telomerase reverse transcriptase mRNA and cytology using bile obtained by endoscopic transpapillary catheterization into the gallbladder for diagnosis of gallbladder carcinoma. Am J Gastroenterol, 98, 2415-9.
  42. Koyanagi Y, Kobayashi D, Yajima T et al (2000). Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells, Anticancer Res, 20, 773-8
  43. Zou S Zhang (2000). Relative risk factors analysis of 3922 cases of gall bladder cancer. Zhonghau Wai Ke Zhi, 11, 805-8.

Cited by

  1. Upregulated long non-coding RNA BC032469 enhances carcinogenesis and metastasis of esophageal squamous cell carcinoma through regulating hTERT expression vol.37, pp.12, 2016,
  2. The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients vol.118, pp.6, 2018,
  3. Oligonucleotides Targeting Telomeres and Telomerase in Cancer vol.23, pp.9, 2018,
  4. Association of TERT-CLPTM1L and 8q24 Common Genetic Variants with Gallbladder Cancer Susceptibility and Prognosis in North Indian Population vol.56, pp.4, 2018,